| Literature DB >> 30988331 |
S A Suphoronski1, R T Chideroli1, C T Facimoto1, R M Mainardi1, F P Souza2, N M Lopera-Barrero2, G F A Jesus3, M L Martins3, G W Di Santis1, A de Oliveira4, G S Gonçalves5, R Dari6, S Frouel6, U P Pereira7.
Abstract
This work evaluated the effects of dietary supplementation of A-Live (phytogenic) either individually or in combination with Aquaform (potassium diformate, acidifier) on juvenile Nile tilapia (Oreochromis niloticus) growth performance, innate immune parameters, gut microbiome, and resistance against Francisella noatunensis subsp. orientalis challenge. Each experimental group contained 140 fishes (34.3 ± 0.33) in two 150L tanks. The experimental design consisted of five groups: a negative control; treated groups (G1, G2, G3) supplemented with different concentrations of A-Live and Aquaform in the feed; and a positive control (PC) for pathogen infection. Groups G1, G2, G3, and PC were challenged with Francisella spp. after 15 days. After infection, the mortality was significantly lower in groups G1, G2, and G3 (p < 0.01). Furthermore, these groups showed significant increase (p < 0.05) in daily weight gain, feed conversion rate, and specific growth rate. The PC group presented increase (p < 0.05) in the leukocytes and neutrophils number. Innate immunity parameters showed no difference between treatments after infection. Microbiome analysis revealed an increased number of bacteria belonging to the Vibrionaceae family after pathogen infection suggesting a secondary pathogen function of these bacteria. These results validate the beneficial effects of these products in tilapia farming.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30988331 PMCID: PMC6465292 DOI: 10.1038/s41598-019-42480-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Visualization of number of cells of Francisella spp. F1 strain by electron microscopy after 30 min of exposure with both products applied either at 0.1% or 1%, (A) (Francisella spp. without the products); (B) (Francisella spp. with A-Live 0.1% and Aquaform 0.1%); (C) (Francisella spp. with A-Live 1% and Aquaform 1%). Cellular damages are shown using white arrows (B,C).
Growth performance of fish from different treatments before and after disease challenge with F. noatunensis subsp. orientalis strain F1.
| Analyzed period | Groups | Initial weight (g) | Final weight (g) | Daily weight gain (g) | Food consumption/fish/day (g) | Feed conversion rate (FCR) | Specific growth rate (SGR) |
|---|---|---|---|---|---|---|---|
| 7 days of acclimation and 15 days of experimental treatment | NC | 35 | 50.6 | 0.74b | 1.63 | 2.19b | 1.75b |
| PC | 36 | 51.1 | 0.72b | 1.66 | 2.31b | 1.66b | |
| G1 | 35 | 49.8 | 0.70b | 1.56 | 2.21b | 1.67b | |
| G2 | 35 | 56.9 | 1.04ª | 1.93 | 1.85ª | 2.31ª | |
| G3 | 33 | 52.7 | 0.94ab | 1.71 | 1.82a | 2.22ab | |
| 14 days post | NC | 50.6 | 60.7 | 0.72ª | 1.01 | 1.40ª | 1.29ª |
| PC | 51.1 | 57.4 | 0.45b | 0.9 | 2.00b | 0.83b | |
|
| 49.8 | 56 | 0.44b | 0.77 | 1.74b | 0.83b | |
|
| 56.9 | 66.3 | 0.67ª | 0.9 | 1.34ª | 1.09ª | |
|
| 52.7 | 61.25 | 0.61a | 0.8 | 1.31ª | 1.07ª |
*Different letters (a and b) indicate significant difference between the treatments (p < 0.05).
NC, negative control; PC, positive control; G1, 0.2% A-Live treatment; G2, 0.2% A-Live and 0.2% Aquaform treatment; G3, 0.5% A-Live and 0.2% Aquaform.
Figure 2Cumulative mortality observed in the different groups after disease challenge by immersion with Francisella noatunensis subsp. orientalis. NC negative control: No challenge with bacteria and no A-Live or Aquaform (2 tanks); PC positive control: Challenge with Francisella spp. and no A-Live or Aquaform; G1- fish that received A-Live at 0.2% in the feed for 15 days prior to experimental infection with Francisella spp. (2 tanks); G2- fish that received the product A-Live at 0.2% and Aquaform at 0.2% in the feed for 15 days prior to experimental infection with Francisella spp.; G3- fish that received the product A-Live at 0.5% and Aquaform at 0.2% in the feed for 15 days prior to experimental infection with Francisella spp. (2 tanks).
Figure 3Histomorphology of the gut with different treatments after 15 days of experimental infection. Shrinkage of intestinal villi are shown using black arrow. Goblet cells are denoted by “*”. (A) G1 group (A-Live at 0.2%); (B) G2 group (A-Live at 0.2% and Aquaform at 0.2%); (C,F): G3 group (A-Live at 0.5% and Aquaform at 0.2%); (D,E) PC group.
Blood general parameters (mean ± standard error) of experimental groups of fish supplemented with additives before and after disease challenge with F. noatunensis subsp. orientalis strain F1.
| Analyzed period | Pre-challenge | Post-challenge | ||||||
|---|---|---|---|---|---|---|---|---|
| Groups | NC | G1 | G2 | G3 | PC |
|
|
|
| Hematocrit (%) | 39.6 ± 3.58 | 29.0 ± 0.79 | 31.2 ± 1.82 | 27.2 ± 2.36 | 31.4 ± 1.24 | 34.8 ± 0.14 | 31.2 ± 0.13 | 27.8 ± 0.18 |
| Hemoglobin (g/dL) | 6.34 ± 0.17a | 5.73 ± 0.08ab | 5.25 ± 0.13b | 5.68 ± 0.08ab | 4.98 ± 0.18 | 5.92 ± 0.59 | 4.66 ± 0.56 | 4.7 ± 0.77 |
| Erythrocytes (106/µL) | 1.96 ± 0.07a | 1.68 ± 0.02ab | 1.23 ± 0.04b | 1.35 ± 0.06b | 1.86 ± 0.08 | 1.91 ± 0.07 | 1.43 ± 0.02 | 1.43 ± 0.04 |
| Thrombocytes (103/µL) | 32.20 ± 1.13ab | 27.90 ± 1.69b | Ag. | 38.95 ± 0.63a | 28.15 ± 1.46 | 30.25 ± 0.96 | 27.61 ± 1.33 | 27.86 ± 0.93 |
| Leukocytes (103/µL) | 53.79 ± 2.04 | 55,12 ± 1.58 | 51.75 ± 0.91 | 39.34 ± 2.83 | 64.12 ± 0.32a | 51.56 ± 1.21b | 55.10 ± 1.87ab | 53.16 ± 1.01b |
| Lymphocytes (103/µL) | 28.89 ± 1.03 | 30.54 ± 0.67 | 30.05 ± 0.82 | 24.22 ± 1.65 | 31.10 ± 0.38 | 30.50 ± 0.55 | 30.18 ± 1.21 | 29.32 ± 0.89 |
| Neutrophils (103/µL) | 21.49 ± 0.98 | 23.30 ± 0.85 | 21.49 ± 0.74 | 14.62 ± 1.40 | 29.70 ± 0.97a | 20.47 ± 1.20b | 24.04 ± 1.15ab | 22.63 ± 0.28ab |
| Monocytes (103/µL) | 3.04 ± 0.25a | 0.84 ± 0.27b | 0.19 ± 0.08b | 0.35 ± 0.13b | 0.81 ± 0.23 | 0.55 ± 0.16 | 0.72 ± 0.20 | 1.20 ± 0.21 |
| Eosinophils (103/µL) | 0.36 ± 0.13 | 0.19 ± 0.09 | 0 ± 0 | 0,10 ± 0.03 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Basophils (103/µL) | 0 ± 0 | 0.23 ± 0.12 | 0 ± 0 | 0.03 ± 0.01 | 0 ± 0 | 0.04 ± 0.02 | 0.12 ± 0.03 | 0 ± 0 |
| MCV (fL) | 203.39 ± 16.01 | 173.13 ± 4.23 | 272.13 ± 26.32 | 221,87 ± 27.42 | 172.48 ± 8.97 | 183.91 ± 5.67 | 222.61 ± 11.14 | 201.47 ± 10.43 |
| MCHC (g/dL) | 19.28 ± 2.50 | 19.91 ± 0.45 | 17.70 ± 1.10 | 23.63 ± 2.08 | 15.97 ± 0.28 | 15.64 ± 0.39 | 15.69 ± 0.80 | 16.86 ± 0.38 |
| Glucose (mg/dL) | 30.15 ± 1.28 | 31.57 ± 2.66 | 31.65 ± 2.76 | 43.29 ± 3.20 | 122.58 ± 13.26 | 91.50 ± 6.78 | 80.16 ± 7.25 | 76.31 ± 9.90 |
*Different letters (a and b) indicate significant difference between the treatments (p < 0.05); *Ag = Aggregated. NC, negative control; PC, positive control; G1, 0.2% A-Live treatment; G2, 0.2% A-Live and 0.2% Aquaform treatment; G3, 0.5% A-Live and 0.2% Aquaform.
Data of serum lysozyme activity, complement activity and antibacterial activity (mean ± standard error) of fish from different groups of treatment before and after disease challenge with F. noatunensis subsp. orientalis strain F1.
| Analyzed period | Pre-challenge | Post-challenge | ||||||
|---|---|---|---|---|---|---|---|---|
| Groups | NC | G1 | G2 | G3 | PC |
|
|
|
| Lysozyme (µg/mL) | 8.77 ± 0.25b | 9.24 ± 0.25ab | 9.43 ± 0.28ab | 11.02 ± 0.19a | 16.76 ± 0.42 | 17.18 ± 0.36 | 17.82 ± 0.43 | 16.73 ± 0.55 |
| Complement activity mean (µL for lysis of 50% of erythrocyte) | 2.11 ± 0.23a | 0.82 ± 0.11b | 0.98 ± 0.09ab | 1.15 ± 0.08ab | 1.07 ± 0.05 | 1.37 ± 0.09 | 1.09 ± 0.10 | 1.06 ± 0.13 |
| Antibacterial activity of serum (Log2 mean of dilution + 1) | 0 ± 0 | 0 ± 0 | 0.32 ± 0.15 | 0.63 ± 0.19 | 0 ± 0 | 1.27 ± 0.29 | 0.63 ± 0.19 | 0.95 ± 0.31 |
*Different letters (a and b) indicate significant difference between the treatments (p < 0.05).
NC, negative control; PC, positive control; G1, 0.2% A-Live treatment; G2, 0.2% A-Live and 0.2% Aquaform treatment; G3, 0.5% A-Live and 0.2% Aquaform.
Figure 4Rarefaction curve showing increasing species along the number of reads in different trial groups.
Figure 5Shannon index in different trial groups after 15 days of treatment and after experimental infection with Francisella spp. (underlined).
Figure 6Abundance of noninfected and infected groups (underlined) with information on the percentage of sequences in each group. Cetobacterium (dark blue), Bacteroidales_unclassified (gray), Vibronaceae_unclassified (yellow), Porphyromonadaceae_unclassified (green), Romboutsia (pink) and Plesiomonas (red).
Count of sequences of the most abundant species in experimental groups.
| Analyzed period | Pre-challenge numbers of sequences (%) | Post-challenge numbers of sequences (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Taxon | NC | G1 | G2 | G3 | PC |
|
|
|
|
| 46733 (94.2) | 97834 (53.5) | 112968 (67.3) | 223726 (81.1) | 105808 (82.5) | 112245 (79.9) | 99783 (79.9) | 61951 (70) |
| Bacteroidales_unclassified | 1486 (3.0) | 65636 (36) | 38781 (23.1) | 36063 (13.1) | 4969 (3.9) | 17860 (12.7) | 6612 (5.3) | 21196 (24) |
|
| 0(0) | 1(0) | 1(0) | 0(0) | 14373 (11.2) | 3879 (2.8) | 14726 (11.8) | 2077 (2.3) |
| Porphyromonadaceae_unclassified | 207 (0.4) | 8756 (4.8) | 4218 (2.5) | 8131 (3) | 833 (0.6) | 1712 (1.2) | 1654 (1.3) | 1445 (1.6) |
| Romboutsia | 876 (1.8) | 8419 (4.6) | 10937 (6.5) | 3477 (1.3) | 22 (0.01) | 239 (0.2) | 460 (0.4) | 55 (0.06) |
|
| 187 (0.4) | 1561 (0.8) | 833 (0.5) | 3221 (1.2) | 1645 (1.3) | 3732 (2.7) | 1260 (1) | 1499 (1.7) |
| Total of reads | 49560 | 182643 | 167955 | 275745 | 128325 | 140541 | 124925 | 88543 |
NC, negative control; PC, positive control; G1, 0.2% A-Live treatment; G2, 0.2% A-Live and 0.2% Aquaform treatment; G3, 0.5% A-Live and 0.2% Aquaform.
Figure 7Comparisons of bacterial abundance among groups. The left side presents the abundance proportion of each sample. The right side shows the difference in abundance within 95% confidence intervals with the p-value of the significance test. Only significant results are displayed (p < 0.05).